Nature of PNH clones in aplastic anemia

被引:0
|
作者
Wanachiwanawin, W [1 ]
Piyawattanasakul, N [1 ]
Visuthisakchai, S [1 ]
Issaragrisil, S [1 ]
机构
[1] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Med, Bangkok 10700, Thailand
关键词
paroxysmal nocturnal hemoglobinuria; aplastic anemia; glycosyl phospatidylinositol proteins;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal, hemolytic disorder characterized by the presence of peripheral blood cells which are deficient in glycosylphosphatidylinositol anchored proteins (GPI - AP). Somatic mutation of the PIG - A gene in a hematopoietic stem cell is responsible for the origin of PNE clone. So far, it is unclear how the mutant stem cell clone dominates hematopoiesis. PNE is closely related to and frequently occurs following aplastic anemia. Our recent study indicated deficient hematopoiesis in vitro in patients with PNH. It is likely that a process inducing bone marrow failure is also responsible for the selection of GPI - AP deficient cells. In order to explore the growth characteristics of PNH clones, we performed regular, repeated flow cytometric analyses of CD59 expression on peripheral blood cells from 32 patients with aplastic anemia. The duration and median time of follow - up were 12-48 and. 20 months, respectively. Twenty - two patients (69%) had one or more occurrences of GPI - AP deficient granulocytes, six of them with PNH erythrocytes on the same occasion. Repeated occurrences of PNH cells (up to four times) were observed in 15 patients (47%). Most of the emerging PNE clones were transient and variable in size. Persistence and expansion of the GPI -. AP deficient populations to the level of clinical PNH were seen in only four patients (12.5%). As the PNH evolved, GPI - AP deficient granulocytes were more apparent than PNH erythrocytes. Our study indicates that PIG - A mutations of hematopoietic stem cells are relatively common among aplastic anemia patients. Our data argue against the concept of an intrinsic growth advantage of PNH clone, on the contrary they support the hypothesis of a selective process which must be persistently strong enough to favor the outgrowth of a GPI - AP deficient population for the evolution of clinical PNH.
引用
收藏
页码:229 / 233
页数:5
相关论文
共 50 条
  • [41] Myelodysplastic syndrome, acute leukemia & PNH after immunosuppressive therapy for severe aplastic anemia
    Socié, G
    Tichelli, A
    PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND RELATED DISORDERS: MOLECULAR ASPECTS OF PATHOGENESIS, 2003, : 199 - 210
  • [42] CHILDHOOD PAROXYSMAL NOCTURNAL HEMOGLOBINURIA/APLASTIC ANEMIA (PNH/AA) SYNDROME - ANALYSIS FOR PNH CLONAL EVOLUTION AFTER IMMUNOSUPPRESSIVE THERAPY
    Sukova, M.
    Mejstrikova, E.
    Pekova, S.
    Cermak, J.
    Popisilova, D.
    Stary, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : S19 - S19
  • [43] Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia
    Patel, Bhumika J.
    Przychodzen, Bartlomiej
    Clemente, Michael J.
    Hirsch, Cassandra M.
    Radivoyevitch, Tomas
    Thota, Swapna
    Nazha, Aziz
    Carraway, Hetty E.
    Sekeres, Mikkael A.
    Maciejewski, Jaroslaw P.
    BLOOD, 2015, 126 (23)
  • [44] Efficacy of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and High Disease Activity with or without History of Aplastic Anemia in the International PNH Registry
    Lee, Jong-Wook
    De latour, Regis Peffault
    Brodsky, Robert A.
    Jang, Jun Ho
    Hill, Anita
    Roeth, Alexander
    Schrezenmeier, Hubert
    Wilson, Amanda
    Marantz, Jing L.
    Maciejewski, Jaroslaw P.
    BLOOD, 2017, 130
  • [45] INCIDENCE AND RISK FACTORS FOR HEMOLYTIC PAROXYSMAL NOCTURNAL HEMOGLOBINUREA (PNH) IN APLASTIC ANEMIA (AA) PATIENTS
    Kulagin, A.
    Golubovskaya, I.
    Ivanova, M.
    Babenko, E.
    Pronkina, N.
    Kruchkova, I.
    Lisukov, I.
    Afanasyev, B.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S42 - S43
  • [46] CONCURRENT TREATMENT OF APLASTIC ANEMIA (AA) WITH IMMUNOSUPPRESSIVE THERAPY AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) WITH ECULIZUMAB
    Griffin, M.
    Hillmen, P.
    Munir, T.
    Richards, S.
    Arnold, L.
    Riley, K.
    Pelton, C.
    Hill, A.
    HAEMATOLOGICA, 2016, 101 : 612 - 612
  • [47] THE PRESENCE OF PNH CLONE IN APLASTIC ANEMIA PATIENTS IS A PROGNOSTIC FACTOR OF GOOD ANSWER ON IMMUNOSUPPRESSIVE THERAPY
    Fidarova, Z.
    Mikhaylova, E.
    Galtseva, I.
    Kliasova, G.
    Lugovskaya, S.
    Naumova, E.
    Troitskaya, V.
    Ustinova, E.
    Tsyba, N.
    Parovichnikova, E.
    Savchenko, V.
    HAEMATOLOGICA, 2014, 99 : 627 - 627
  • [48] EVOLUTION OF MODERATE APLASTIC ANEMIA INTO SUBCLINICAL PNH/AA & SUCCESSFUL TREATMENT WITH HAPLO- BMT
    Srinivas, Meghana
    Krajewski, Jennifer
    Hankewycz, Melanie
    Durning, Nancy
    Gillio, Alfred
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S15 - S16
  • [49] Small populations of PNH-Type cells in aplastic anemia patients are derived from PIG-A mutant stem cell clones without proliferative advantage.
    Mochizuki, Kanako
    Sugimori, Chiharu
    Feng, Xingmin
    Lu, Xuzhang
    Reed, Gudrun H.
    Wittwer, Carl T.
    Nakao, Shinji
    BLOOD, 2006, 108 (11) : 291A - 291A
  • [50] Rapid and sensitive single tube screen for paroxysmal nocturnal hemoglobinuria (PNH) clones in aplastic anemia, myelodysplastic syndrome and bone marrow failure syndromes by multiparameter flow cytometry
    Movalia, Mayur K.
    Illingworth, Andrea
    BLOOD, 2007, 110 (11) : 1075A - 1075A